PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. 1995 February; 63(2): 547–553.
PMCID: PMC173030

Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity.

Abstract

It has been postulated that systemic cell-mediated immunity (CMI) is an important host defense mechanism against Candida infections of the vagina. However, in an estrogen-dependent murine model of experimental vaginal candidiasis, we recently showed that systemic Candida-specific Th1-type CMI induced by immunization with Candida culture filtrate antigen had no effect on vaginal Candida population levels during the course of a vaginal infection. In the present study, mice given a second vaginal inoculation in the presence of peripheral Candida-specific Th1-type CMI induced by prior vaginal infection had anamnestic-type increased delayed-type hypersensitivity (DTH) responses, concomitant with significantly fewer Candida organisms in the vagina than in primary-infected mice. In addition, organisms in secondary-infected mice were fragmented and superficial penetration into the epithelium was reduced. The systemic presence of Candida-specific T suppressor (Ts) cells that significantly suppressed the infection-derived anamnestic DTH reactivity did not abrogate the protective effect in the vagina. Additional experiments showed that vaginally immunized mice were not protected from gastrointestinal or systemic candidiasis and, in contrast to mice with a second vaginal infection, did not demonstrate anamnestic DTH reactivity. These results suggest that a moderate level of local protection against a Candida vaginal infection can be achieved by vaginal immunization but that the protective role of acquired peripheral Candida-specific Th1-type reactivity at the vaginal mucosa appears to be limited.

Full Text

The Full Text of this article is available as a PDF (572K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Balish E, Filutowicz H, Oberley TD. Correlates of cell-mediated immunity in Candida albicans-colonized gnotobiotic mice. Infect Immun. 1990 Jan;58(1):107–113. [PMC free article] [PubMed]
  • Cantorna MT, Balish E. Role of CD4+ lymphocytes in resistance to mucosal candidiasis. Infect Immun. 1991 Jul;59(7):2447–2455. [PMC free article] [PubMed]
  • Domer JE, Human LG, Andersen GB, Rudbach JA, Asherson GL. Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A. Infect Immun. 1993 May;61(5):2122–2130. [PMC free article] [PubMed]
  • Dunn PL, North RJ. Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4- CD8- cells. J Infect Dis. 1991 Nov;164(5):869–877. [PubMed]
  • Ehlers S, Mielke ME, Blankenstein T, Hahn H. Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with Listeria monocytogenes. The immediate early phase in innate resistance and acquired immunity. J Immunol. 1992 Nov 1;149(9):3016–3022. [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun. 1993 May;61(5):1990–1995. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun. 1993 Oct;61(10):4202–4207. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Sobel JD. Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun. 1994 Mar;62(3):1032–1038. [PMC free article] [PubMed]
  • Fidel PL, Jr, Lynch ME, Redondo-Lopez V, Sobel JD, Robinson R. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis. 1993 Dec;168(6):1458–1465. [PubMed]
  • Fischer A, Ballet JJ, Griscelli C. Specific inhibition of in vitro Candida-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest. 1978 Nov;62(5):1005–1013. [PMC free article] [PubMed]
  • Fleury FJ. Adult vaginitis. Clin Obstet Gynecol. 1981 Jun;24(2):407–438. [PubMed]
  • Fong IW, McCleary P, Read S. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am J Obstet Gynecol. 1992 Mar;166(3):887–890. [PubMed]
  • Garner RE, Domer JE. Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis. Infect Immun. 1994 Feb;62(2):738–741. [PMC free article] [PubMed]
  • Hersh EV, Gutterman JU, Mavligit GM. Effect of haematological malignancies and their treatment on host defence factors. Clin Haematol. 1976 Jun;5(2):425–448. [PubMed]
  • Hobbs JR, Brigden D, Davidson F, Kahan M, Oates JK. Immunological aspects of candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):11–14. [PMC free article] [PubMed]
  • Hurley R. Candidal vaginitis. Proc R Soc Med. 1977;70 (Suppl 4):1–2. [PMC free article] [PubMed]
  • Hurley R. Recurrent Candida infection. Clin Obstet Gynaecol. 1981 Apr;8(1):209–214. [PubMed]
  • Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979 Sep;55(647):645–647. [PMC free article] [PubMed]
  • Igietseme JU, Rank RG. Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Infect Immun. 1991 Apr;59(4):1346–1351. [PMC free article] [PubMed]
  • Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. [PubMed]
  • Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J Infect Dis. 1971 Apr;123(4):371–377. [PubMed]
  • Macher AM. The pathology of AIDS. Public Health Rep. 1988 May-Jun;103(3):246–254. [PMC free article] [PubMed]
  • Morton RS, Rashid S. Candidal vaginitis: natural history, predisposing factors and prevention. Proc R Soc Med. 1977;70 (Suppl 4):3–6. [PMC free article] [PubMed]
  • Müller I, Kropf P, Etges RJ, Louis JA. Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun. 1993 Sep;61(9):3730–3738. [PMC free article] [PubMed]
  • Nandi D, Allison JP. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol. 1991 Sep 15;147(6):1773–1778. [PubMed]
  • Narayanan R, Joyce WA, Greenfield RA. Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun. 1991 Jun;59(6):2116–2119. [PMC free article] [PubMed]
  • Paterson PY, Semo R, Blumenschein G, Swelstad J. Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. Clin Exp Immunol. 1971 Nov;9(5):595–602. [PubMed]
  • Polonelli L, De Bernardis F, Conti S, Boccanera M, Gerloni M, Morace G, Magliani W, Chezzi C, Cassone A. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol. 1994 Mar 15;152(6):3175–3182. [PubMed]
  • Rogers TJ, Balish E. Effect of systemic candidiasis on blastogenesis of lymphocytes from germfree and conventional rats. Infect Immun. 1978 Apr;20(1):142–150. [PMC free article] [PubMed]
  • Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P, Bistoni F. Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun. 1991 Dec;59(12):4647–4654. [PMC free article] [PubMed]
  • Romani L, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Puccetti P, Bistoni F. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol. 1993 Feb 1;150(3):925–931. [PubMed]
  • Sieck TG, Moors MA, Buckley HR, Blank KJ. Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line. Infect Immun. 1993 Aug;61(8):3540–3543. [PMC free article] [PubMed]
  • Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci. 1988;544:547–557. [PubMed]
  • Syverson RE, Buckley H, Gibian J, Ryan GM., Jr Cellular and humoral immune status in women with chronic Candida vaginitis. Am J Obstet Gynecol. 1979 Jul 15;134(6):624–627. [PubMed]
  • Witkin SS. Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans. Obstet Gynecol. 1986 Nov;68(5):696–699. [PubMed]
  • Witkin SS, Hirsch J, Ledger WJ. A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors. Am J Obstet Gynecol. 1986 Oct;155(4):790–795. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)